Cent Eur J Public Health 2008, 16(Supplement):S17-S18

HPV DNA Detection Assays for Cervical Screening

Peter J. F. Snijders1, Daniëlle A. M. Heideman1, Bart T. Hesselink1, Johannes Berkhof2, Chris J. L. M. Meijer1
1 Department of Pathology
2 Department of Clinical Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands

Various high-risk HPV (hr HPV) DNA assays have been developed that allow detection of a broad spectrum of HR HPVs. Two of these assays [Hybrid Capture 2 (hc2) and GP5+/6+-PCR] have shown in large clinical trials a superior clinical sensitivity for cervical (pre)cancer compared to cytology and an optimal balance between clinical sensitivity and pecificity. Comparative studies showed that an increased sensitivity for HR HPV relative to GP5+/6+-PCR and/or hc2 results in a dramatic decrease in clinical specificity, whereas on the other hand a decreased sensitivity for virus leads to a decrease in sensitivity for (pre)cancer. These data argue for guidelines on HR HPV test requirements for cervical screening purposes.

Keywords: human papillomavirus, cervical cancer, high-grade CIN, HPV DNA testing, clinical performance

Published: April 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Snijders PJF, Heideman DAM, Hesselink BT, Berkhof J, Meijer CJLM. HPV DNA Detection Assays for Cervical Screening. Cent Eur J Public Health. 2008;16(Supplement):S17-18.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Brink AA, Snijders PJ, Meijer CJ, Berkhof J, Verheijen RH. HPV testing in cervical screening. Best Pract Res Clin Obstet Gynaecol. 2006 Apr;20(2):253-66. Go to original source... Go to PubMed...
    2. Bulk S, Bulkmans NW, Berkhof J, Rozendaal L, Boeke AJ, Verheijen RH, et al. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int J Cancer. 2007 Jul 15;121(2):361-7. Erratum in: Int J Cancer. 2007 Oct 15;121(8):1873. Go to original source... Go to PubMed...
    3. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al; Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007 Oct 18;357(16):1579-88. Go to original source... Go to PubMed...
    4. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007 Oct 18;357(16):1589-97. Go to original source... Go to PubMed...
    5. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007 Nov 24;370(9601):1764-72. Go to original source... Go to PubMed...
    6. HesselinkAT, van Ham MAPC, Heideman DAM, Groothuismink ZMA, Rozendaal L, Berkhof J, et al. Comparison of GP5+/6+-PCR and SPF10 high-risk HPVassays for detecting women with normal cytology developing cervical intraepithelial neoplasia grade 3. Chapter 4. In: Hesselink AT. High-risk human papillomavirus testing in cervical screening: which assay? Enschede: PrintPartners Ipskamp; 2007. p. 51-62.
    7. HesselinkAT, Bulkmans NW, Berkhof J, LorinczAT, Meijer CJ, Snijders PJ. Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J Clin Microbiol. 2006 Oct;44(10):3680-5. Go to original source... Go to PubMed...

    Return to the content